This segment focuses on leveraging Lantern Pharma's proprietary RADR® AI platform to accelerate and improve the drug discovery and development process. Research and development activities include the use of machine learning and genomics to identify and validate novel drug targets, predict drug efficacy, and optimize clinical trial design. The company utilizes its AI platform to analyze vast datasets of genomic and clinical data to identify biomarkers and patient populations most likely to benefit from its drug candidates. This segment's therapeutic areas include oncology, with a focus on precision medicine approaches. Patient impact is addressed by developing targeted therapies that aim to improve outcomes and reduce side effects. Market positioning is based on the company's AI platform, which provides a competitive advantage in terms of speed, cost, and accuracy in drug development. Future opportunities include expanding the platform's capabilities and applying it to a broader range of cancers and therapeutic areas. Clinical trials and regulatory aspects are crucial, with the company actively conducting clinical trials to validate its drug candidates and obtain regulatory approvals. Partnerships and collaborations with research institutions and pharmaceutical companies are essential for advancing the development and commercialization of its therapies.

This segment encompasses the development and clinical testing of targeted oncology therapies. The primary focus is on developing drug candidates like LP-100 (for metastatic, castration-resistant prostate cancer), LP-300 (combination therapy for non-small cell lung cancer adenocarcinoma), and LP-184 (alkylating agent). Research and development activities include conducting clinical trials, analyzing clinical data, and optimizing drug formulations. The technologies and methodologies used include genomics, machine learning, and AI to identify patients who will benefit most from the therapies. The therapeutic areas covered are primarily oncology, with a focus on prostate cancer and non-small cell lung cancer. The patient impact is aimed at improving survival rates and quality of life for cancer patients. Market positioning is based on the development of precision medicine approaches that target specific cancer types and patient populations. Future opportunities include expanding the pipeline with new drug candidates and expanding clinical trials to include additional cancer types. Regulatory and clinical aspects are critical, with the company working closely with regulatory agencies to obtain approvals for its therapies. Partnerships and collaborations with research institutions and pharmaceutical companies are essential for advancing the development and commercialization of its therapies.